Hirobumi Ito, Sasuga Yasuhiro
Otolaryngology, Ito ENT Clinic, Funabashi, JPN.
Laboratory, B&S Corporation Hachioji Research and Development Center, Tokyo, JPN.
Cureus. 2023 Jul 4;15(7):e41374. doi: 10.7759/cureus.41374. eCollection 2023 Jul.
Sublingual immunotherapy (SLIT), in which standardized cedar pollen extract solution is administered, has been used to treat cedar pollinosis, but SLIT is problematic because it takes a long time to become effective, and some cases are ineffective even after long-term treatment. It has also been reported that lactobacillus acidophilus extract (LEX), a food-derived ingredient, alleviates various allergic symptoms. This study examined the usefulness of LEX as a treatment for cedar pollinosis in comparison with SLIT. We also examined whether the combined use of SLIT and LEX could have an early-onset of therapeutic effect on cedar pollinosis. We also examined the usefulness of LEX as a salvage therapy for patients who failed to respond to SLIT.
Fifteen patients with cedar pollinosis were divided into three groups. The three groups were: three patients in the standardized cedar pollen extract group (S group), seven patients in the lactobacillus-producing extract group (L group), and five patients in the combination group of standardized cedar pollen extract and lactobacillus-producing extract (SL group). The subjects were treated for three years, corresponding to the three scattering seasons of cedar pollen, and observed according to the evaluation items. The evaluation items were severity score based on examination findings, subjective symptom score (QOL score) based on the Japanese Standard QOL Questionnaire for Allergic Rhinitis (JRQLQ No. 1) questionnaire, nonspecific IgE level measurement by blood test, and cedar pollen-specific IgE level measurement.
After three years of observation, there were no significant differences in severity score and nonspecific IgE levels among the three groups, while QOL score decreased significantly between the first and third years of treatment in the L group. Cedar pollen-specific IgE levels in the S and SL groups showed an increase in the first year and a gradual decrease in the second and third years of treatment compared to the pre-treatment period. In group L, no increase was observed in the first year, and a significant decrease was observed in the second and third years during the cedar pollen dispersal period.
The results of severity and quality of life scores indicated that it took three years of treatment for the S and SL groups to show efficacy, while the L group showed improvement in quality of life scores and cedar pollen-specific IgE levels from the first year, suggesting that LEX is useful as a treatment for cedar pollinosis. The efficacy of combination therapy with SLIT and LEX was not clear, but since the effect of LEX was observed from the early stage of treatment, it was thought that the combination therapy with LEX intake from the early stage of treatment may be effective in reducing the incidence of ineffective cases. The combination therapy of SLIT and LEX may also be useful as a salvage therapy.
舌下免疫疗法(SLIT),即给予标准化雪松花粉提取液,已被用于治疗雪松花粉症,但SLIT存在问题,因为其起效时间长,且部分病例即使经过长期治疗仍无效。也有报道称,食品来源成分嗜酸乳杆菌提取物(LEX)可减轻各种过敏症状。本研究比较了LEX与SLIT治疗雪松花粉症的有效性。我们还研究了SLIT与LEX联合使用是否能对雪松花粉症产生早期治疗效果。我们还研究了LEX作为对SLIT无反应患者的挽救疗法的有效性。
15例雪松花粉症患者分为三组。三组分别为:标准化雪松花粉提取物组(S组)3例患者,嗜酸乳杆菌提取物组(L组)7例患者,标准化雪松花粉提取物与嗜酸乳杆菌提取物联合组(SL组)5例患者。受试者接受为期三年的治疗,对应雪松花粉的三个散播季节,并根据评估项目进行观察。评估项目包括基于检查结果的严重程度评分、基于日本变应性鼻炎标准生活质量问卷(JRQLQ No.1)问卷的主观症状评分(生活质量评分)、通过血液检测测量非特异性IgE水平以及测量雪松花粉特异性IgE水平。
经过三年观察,三组间严重程度评分和非特异性IgE水平无显著差异,而L组在治疗的第一年和第三年生活质量评分显著下降。S组和SL组的雪松花粉特异性IgE水平在治疗的第一年有所升高,与治疗前相比,在第二年和第三年逐渐下降。在L组,第一年未观察到升高,在雪松花粉散播期的第二年和第三年观察到显著下降。
严重程度和生活质量评分结果表明,S组和SL组需要三年治疗才显示出疗效,而L组从第一年起生活质量评分和雪松花粉特异性IgE水平就有所改善,表明LEX可作为雪松花粉症的一种治疗方法。SLIT与LEX联合治疗的疗效尚不清楚,但由于从治疗早期就观察到LEX的效果,因此认为从治疗早期开始摄入LEX的联合治疗可能有效降低无效病例的发生率。SLIT与LEX的联合治疗也可能作为一种挽救疗法有用。